CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Pliant Therapeutics, Inc. - PLRX CFD

14.53
0%
Market Trading Hours* (UTC) Open now
Closes on Wednesday at 21:00

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.20
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024346 %
Charges from full value of position ($-0.24)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
-0.024346%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.002124 %
Charges from full value of position ($0.02)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
0.002124%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 50.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 14.32
Open 13.68
1-Year Change -18.33%
Day's Range 13.68 - 14.59
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 17, 2024 14.32 0.75 5.53% 13.57 14.59 13.53
Dec 16, 2024 13.69 0.52 3.95% 13.17 13.78 13.01
Dec 13, 2024 13.27 -0.36 -2.64% 13.63 13.63 13.03
Dec 12, 2024 13.81 -0.18 -1.29% 13.99 13.99 13.53
Dec 11, 2024 14.16 -0.31 -2.14% 14.47 14.48 13.92
Dec 10, 2024 14.49 0.18 1.26% 14.31 14.82 14.31
Dec 9, 2024 14.82 0.14 0.95% 14.68 15.19 14.68
Dec 6, 2024 14.68 0.79 5.69% 13.89 14.94 13.87
Dec 5, 2024 14.23 -0.04 -0.28% 14.27 14.60 13.97
Dec 4, 2024 14.66 0.12 0.83% 14.54 14.93 14.28
Dec 3, 2024 14.62 -0.72 -4.69% 15.34 15.73 14.27
Dec 2, 2024 15.47 1.70 12.35% 13.77 15.61 13.77
Nov 29, 2024 13.77 0.26 1.92% 13.51 13.81 13.19
Nov 27, 2024 13.50 0.25 1.89% 13.25 13.65 13.00
Nov 26, 2024 13.31 0.28 2.15% 13.03 13.56 12.97
Nov 25, 2024 13.41 0.44 3.39% 12.97 13.57 12.97
Nov 22, 2024 12.93 0.09 0.70% 12.84 13.25 12.71
Nov 21, 2024 12.81 0.18 1.43% 12.63 13.24 12.47
Nov 20, 2024 12.69 0.11 0.87% 12.58 12.70 12.16
Nov 19, 2024 12.76 0.78 6.51% 11.98 12.89 11.95

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
Leverage
2:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Pliant Therapeutics, Inc. Company profile

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. It focuses in treating fibrosis by inhibiting integrin-mediated activation of transforming growth factor beta (TGF-B). Its lead product candidate, PLN-74809, is an oral small-molecule, dual-selective inhibitor of avß6 and avB1. The Company’s second product candidate, PLN-1474, is a small-molecule, selective inhibitor of avB1 for treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition to its clinical programs, it is developing additional preclinical integrin-based programs. The first preclinical program is oncology program. Its second preclinical program is an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor being developed for treatment of muscular dystrophies, including duchenne muscular dystrophy.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Pliant Therapeutics Inc revenues decreased 82% to $7.6M. Net loss increased from $41.5M to $97.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 14% to $73.6M (expense), General and administrative - Balancing increase of 39% to $21M (expense).

Industry: Pharmaceuticals (NEC)

260 Littlefield Avenue
Suite 150
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

People also watch

ETH/USD

3,849.21 Price
-1.780% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

XRP/USD

2.50 Price
-2.820% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01249

Gold

2,639.72 Price
-0.270% 1D Chg, %
Long position overnight fee -0.0055%
Short position overnight fee -0.0027%
Overnight fee time 22:00 (UTC)
Spread 0.30

US100

21,921.20 Price
-0.070% 1D Chg, %
Long position overnight fee -0.0243%
Short position overnight fee 0.0021%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading